June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Differential effects of bimatoprost vs. bimatoprost free acid on outflow cell MMPs
Author Affiliations & Notes
  • Kristin Perkumas
    Ophthalmology, Duke University, Durham, North Carolina, United States
  • Douglas J Rhee
    Case Western Reserve University, Cleveland, Ohio, United States
  • Daniel W Stamer
    Ophthalmology, Duke University, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Kristin Perkumas, None; Douglas Rhee, Allergan (F), Allergan (C); Daniel Stamer, Allergan (F), Allergan (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 551. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kristin Perkumas, Douglas J Rhee, Daniel W Stamer; Differential effects of bimatoprost vs. bimatoprost free acid on outflow cell MMPs. Invest. Ophthalmol. Vis. Sci. 2021;62(8):551.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In clinical trials, the intracameral bimatoprost SR implant lowers intraocular pressure (IOP) well beyond cessation of drug release by the implant. Since matrix metalloprotease (MMP) activity underlies topical bimatoprost effects on IOP, we hypothesized that long-term effects of bimatoprost SR was due to effects of dramatically elevated outflow tissue levels of unmetabolized bimatoprost (amide, not bimatoprost free acid (BFA)) on MMP activity in outflow pathway cells.

Methods : Human outflow pathway cells (trabecular meshwork, TM, n=7; ciliary muscle, CM, n=6; scleral fibroblasts, SF as controls, n=4) in culture were treated with either implant tissue levels of bimatoprost (10–1000 µM) or topical tissue levels of BFA (0.1–10 µM). Cells were exposed to drug for 24 hours, and MMP gene expression was measured by PCR array and MMP1 protein by ELISA.

Results : Compared to all other treatments, implant levels of bimatoprost (1000 µM) significantly altered expression of the greatest number of genes in all cell types (e.g.: n=11 partially overlapping genes in TM and CM cells, p<0.05,). Despite these significant effects, there was noticeable strain to strain differences in responses to implant levels of bimatoprost. By comparison, only two genes were significantly altered in TM and CM cells with topical outflow tissue levels of BFA (10 µM). In the one glaucomatous TM cell strain tested, implant levels of bimatoprost had similar effects on most genes compared to normal cells. However, 1000 µM bimatoprost dramatically increased MMP1 and MMP10 expression in glaucomatous TM cells well above average responses of normal TM cells (183.8 vs. 62.9±66.4 fold, and 52.1 vs. 2.89±2.4 fold, respectively), both genes of which were dose-dependently upregulated in normal TM cells, but not CM cells. Similarly, MMP1 protein levels were dose-dependently upregulated in TM, but not CM cells.

Conclusions : Bimatoprost and BFA had differential effects on MMP gene expression, with a dramatic upregulation in MMP1 in TM cells seen only at “implant levels” of bimatoprost. These preferential effects of high dose bimatoprost on MMP expression on TM cells suggests that increased conventional outflow is due to durable tissue remodeling, underlying long term IOP benefit of implant in some patients.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×